Evidence map›Paper›PMID 26078790›Full record

ArticleJournal of Cancer2015

Predictors that Influence Election of Contralateral Prophylactic Mastectomy among Women with Ductal Carcinoma in Situ who are BRCA-Negative.

Nisreen Elsayegh, Jessica Profato, Angelica M Gutierrez Barrera, Heather Lin, Henry M Kuerer, Can Ardic, Jennifer K Litton, Debasish Tripathy, Banu K Arun

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of Cancer, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Nisreen Elsayegh1. Clinical Cancer Genetics, the University of Texas MD Anderson Cancer Center, Houston, TX.
Jessica Profato1. Clinical Cancer Genetics, the University of Texas MD Anderson Cancer Center, Houston, TX.
Angelica M Gutierrez Barrera2. Department of Breast Medical Oncology, the University of Texas MD Anderson Cancer Center, Houston, TX.
Heather Lin3. Department of Biostatistics, the University of Texas MD Anderson Cancer Center, Houston, TX.
Henry M Kuerer4. Department of Surgical Oncology, the University of Texas MD Anderson Cancer Center, Houston, TX.
Can Ardic2. Department of Breast Medical Oncology, the University of Texas MD Anderson Cancer Center, Houston, TX.
Jennifer K Litton2. Department of Breast Medical Oncology, the University of Texas MD Anderson Cancer Center, Houston, TX.
Debasish Tripathy2. Department of Breast Medical Oncology, the University of Texas MD Anderson Cancer Center, Houston, TX.
Banu K Arun1. Clinical Cancer Genetics, the University of Texas MD Anderson Cancer Center, Houston, TX ; 2. Department of Breast Medical Oncology, the University of Texas MD Anderson Cancer Center, Houston, TX.

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
NCI NIH HHS P30 CA016672
6 · The paper itself

Abstract

The authors retrospectively examined the contralateral prophylactic mastectomy (CPM) rate among 100 women with ductal carcinoma in situ who are BRCA negative. Of 100 women with ductal carcinoma in situ, 31 elected contralateral prophylactic mastectomy (CPM). Factors associated with increased likelihood of undergoing contralateral prophylactic mastectomy (CPM) among this cohort were: family history of ovarian cancer, marital status, reconstruction, mastectomy of the affected breast, and tamoxifen use.

Indexed as

BRCA negativecontralateral prophylactic mastectomy

Identifiers

PMID26078790
PMCPMC4466409

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.